Needham analyst Stephen Unger maintained a Buy rating on Personalis (NASDAQ:PSNL) Inc on Thursday, setting a price target of $32, which is approximately 8.70% above the present share price of $29.44.
Unger expects Personalis Inc to post earnings per share (EPS) of -$0.27 for the fourth quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Personalis, with an average price target of $31.8.
The analysts price targets range from a high of $35 to a low of $27.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $19.82 million and a net profit of -$9.65 million. The company's market cap is $1.15 billion.
According to TipRanks.com, Needham analyst Stephen Unger is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 36.4% and a 76.34% success rate.
Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.